These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 7686838

  • 21. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system.
    Schaefer BM, Stark HJ, Fusenig NE, Todd RF, Kramer MD.
    Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451
    [Abstract] [Full Text] [Related]

  • 22. The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
    Zhu C, Jiang L, Xu J, Ren A, Ju F, Shu Y.
    Pathol Res Pract; 2020 Apr; 216(4):152885. PubMed ID: 32113794
    [Abstract] [Full Text] [Related]

  • 23. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM, Han DM, Yu ZK, Fan EZ, Li Y.
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
    [Abstract] [Full Text] [Related]

  • 24. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
    Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J.
    Br J Cancer; 1994 Feb; 69(2):398-405. PubMed ID: 8297742
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney.
    Xu Y, Hagege J, Mougenot B, Sraer JD, Rønne E, Rondeau E.
    Kidney Int; 1996 Dec; 50(6):2011-9. PubMed ID: 8943484
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
    Buø L, Bjørnland K, Karlsrud TS, Kvale D, Kjønniksen I, Fodstad O, Brandtzaeg P, Johansen HT, Aasen AO.
    Anticancer Res; 1994 Dec; 14(6B):2445-51. PubMed ID: 7872665
    [Abstract] [Full Text] [Related]

  • 29. Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
    Ito Y, Takeda T, Kobayashi T, Wakasugi E, Tamaki Y, Umeshita K, Monden T, Shimano T, Monden M.
    Anticancer Res; 1996 Dec; 16(1):81-9. PubMed ID: 8615674
    [Abstract] [Full Text] [Related]

  • 30. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.
    Chambers SK, Ivins CM, Carcangiu ML.
    Int J Cancer; 1998 Oct 23; 79(5):449-54. PubMed ID: 9761111
    [Abstract] [Full Text] [Related]

  • 31. Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization.
    Morita S, Sato A, Hayakawa H, Ihara H, Urano T, Takada Y, Takada A.
    Int J Cancer; 1998 Oct 29; 78(3):286-92. PubMed ID: 9766559
    [Abstract] [Full Text] [Related]

  • 32. The expression of plasminogen activator system in a rat model of periodontal wound healing.
    Xiao Y, Li H, Bunn C, Bartold PM.
    J Periodontol; 2001 Jul 29; 72(7):849-57. PubMed ID: 11495131
    [Abstract] [Full Text] [Related]

  • 33. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
    Robert C, Bolon I, Gazzeri S, Veyrenc S, Brambilla C, Brambilla E.
    Clin Cancer Res; 1999 Aug 29; 5(8):2094-102. PubMed ID: 10473092
    [Abstract] [Full Text] [Related]

  • 34. Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
    Naitoh H, Eguchi Y, Ueyama H, Kodama M, Hattori T.
    Jpn J Cancer Res; 1995 Jan 29; 86(1):48-56. PubMed ID: 7737909
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
    Pedersen H, Grøndahl-Hansen J, Francis D, Osterlind K, Hansen HH, Danø K, Brünner N.
    Cancer Res; 1994 Jan 01; 54(1):120-3. PubMed ID: 8261432
    [Abstract] [Full Text] [Related]

  • 37. Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
    Caccamo DV, Keohane ME, McKeever PE.
    Mod Pathol; 1994 Jan 01; 7(1):99-104. PubMed ID: 8159659
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.